Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Details

General Information of the Drug (ID: DR3731)
Name
Bevacizumab
Synonyms
Bevacizumab (ophthalmic slow-release tissue tablet)
    Click to Show/Hide
Molecular Type
Antibody
Disease Colorectal cancer [ICD-11: 2B91] Approved [1]
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
TTD Drug ID
D04KBL
DrugBank ID
DB00112
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Ellagic acid      Lagerstroemia speciosa     Click to Show/Hide the Molecular Data of This NP
                 Augmenting Drug Sensitivity     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation
Down-regulation Expression ABCB1  Molecule Info 
Pathway MAP
Up-regulation Expression CASP3  Molecule Info 
Pathway MAP
Down-regulation Expression MGMT  Molecule Info 
Pathway MAP
Up-regulation Expression TP53  Molecule Info 
Pathway MAP
                    In-vitro Model C6 CVCL_0194 Rat malignant glioma Rattus norvegicus
                    Experimental
                    Result(s)
Antiproliferative efficacy of EA combined with BEV, probably through inhibition of MGMT expression and time-dependent inhibition of MDR1.
          Triamcinolone      Cladosporium     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model A case report
                    Experimental
                    Result(s)
Combination in close sequence resulted in a dramatic improvement in vision and cystoid macular edema.
Target and Pathway
Target(s) Vascular endothelial growth factor A (VEGFA)  Molecule Info  [1]
KEGG Pathway Ras signaling pathway Click to Show/Hide
2 Rap1 signaling pathway
3 Cytokine-cytokine receptor interaction
4 HIF-1 signaling pathway
5 mTOR signaling pathway
6 PI3K-Akt signaling pathway
7 VEGF signaling pathway
8 Focal adhesion
9 Pathways in cancer
10 Proteoglycans in cancer
11 MicroRNAs in cancer
12 Renal cell carcinoma
13 Pancreatic cancer
14 Bladder cancer
15 Rheumatoid arthritis
NetPath Pathway IL2 Signaling Pathway Click to Show/Hide
2 EGFR1 Signaling Pathway
3 TGF_beta_Receptor Signaling Pathway
4 TSH Signaling Pathway
5 Leptin Signaling Pathway
6 FSH Signaling Pathway
Panther Pathway Angiogenesis Click to Show/Hide
2 VEGF signaling pathway
Pathway Interaction Database Glypican 1 network Click to Show/Hide
2 HIF-2-alpha transcription factor network
3 Beta3 integrin cell surface interactions
4 S1P3 pathway
5 Signaling events mediated by TCPTP
6 S1P1 pathway
7 Alpha9 beta1 integrin signaling events
8 Integrins in angiogenesis
9 VEGFR1 specific signals
10 HIF-1-alpha transcription factor network
Reactome Platelet degranulation Click to Show/Hide
2 Regulation of gene expression by Hypoxia-inducible Factor
3 VEGF ligand-receptor interactions
4 VEGF binds to VEGFR leading to receptor dimerization
WikiPathways SIDS Susceptibility Pathways Click to Show/Hide
2 Hypertrophy Model
3 Endochondral Ossification
4 Focal Adhesion
5 Differentiation Pathway
6 Bladder Cancer
7 Regulation of Hypoxia-inducible Factor (HIF) by Oxygen
8 Nifedipine Activity
9 Aryl Hydrocarbon Receptor
10 Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis
11 Integrated Pancreatic Cancer Pathway
12 Oncostatin M Signaling Pathway
13 Allograft Rejection
14 Integrated Breast Cancer Pathway
15 Signaling by VEGF
16 Heart Development
17 Angiogenesis
References
Reference 1 FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
Reference 2 Ellagic Acid Enhances the Antitumor Efficacy of Bevacizumab in an In Vitro Glioblastoma Model. World Neurosurg. 2019 Dec;132:e59-e65.
Reference 3 Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone. Eye (Lond). 2007 Aug;21(8):1128-30.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China